Rilzabrutinib for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine

NCT05107115 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
161
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Sanofi